发明名称 |
FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR MONITORING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE |
摘要 |
Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.
|
申请公布号 |
US2012276059(A1) |
申请公布日期 |
2012.11.01 |
申请号 |
US201213457049 |
申请日期 |
2012.04.26 |
申请人 |
BOONE JAMES HUNTER;LYERLY DAVID M.;WILKINS TRACY D.;CARMAN ROBERT J.;TECHLAB, INC. |
发明人 |
BOONE JAMES HUNTER;LYERLY DAVID M.;WILKINS TRACY D.;CARMAN ROBERT J. |
分类号 |
G01N33/569;A61K31/4164;A61K35/74;A61K38/16;C12Q1/18;C12Q1/68;G01N33/573 |
主分类号 |
G01N33/569 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|